Geeta Jain
Head of Investor Relations
Replay available
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call
Definium Therapeutics, Inc. (NASDAQ: DFTX) Q1 2026 earnings conference call, held 2026-05-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Rob Barrow
Chief Executive Officer
Dr. Dan Carlin
Chief Medical Officer
Matt Wiley
Chief Commercial Officer
Brandy Roberts
Chief Financial Officer
Brian Bolton
Analyst, Jefferies (for Andrew Tsai)
Francois Prespoys
Analyst, LifeSide Capital
Chris Chen
Analyst, Baird
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Definium Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.535 Good afternoon. I am Geeta Jain, Head of Investor Relations, and thank you for joining 00:00:04.535 -- 00:00:09.620 us today for DFINIUM Therapeutics' first quarter, 2026, financial results 00:00:09.620 -- 00:00:14.345 and recent highlights conference call. Currently, all participants are in listen-only 00:00:14.345 -- 00:00:20.731 mode. This webcast is live on the investor section of DFINIUM's website at DFINIUMTX.com, 00:00:20.731 -- 00:00:24.275 and a replay will be available after the webcast. 00:00:24.275 -- 00:00:29.020 Leading the call today will be Rob Barrow, our Chief Executive Officer, who is joined 00:00:29.020 -- 00:00:34.585 by Dr. Dan Carlin, our Chief Medical Officer, Brandy Roberts, our Chief Financial Officer, 00:00:34.585 -- 00:00:37.929 and Matt Wiley, our Chief Commercial Officer. 00:00:37.929 -- 00:00:42.173 During today's call, we will be making certain forward-looking statements, including 00:00:42.173 -- 00:00:47.018 without limitation statements about the potential safety, efficacy, and regulatory and 00:00:47.018 -- 00:00:51.903 clinical progress of our product candidates, our anticipated cash runaway, and our future 00:00:51.903 -- 00:00:55.516 expectations, plans, partnerships, and prospects. 00:00:55.516 -- 00:01:00.080 These statements are subject to various risks, such as changes in market conditions and 00:01:00.080 -- 00:01:05.105 difficulties associated with research and development and regulatory approval processes. 00:01:05.105 -- 00:01:09.569 These and other risk factors are described in the filings made with the SEC and the applicable 00:01:09.569 -- 00:01:14.554 Canadian securities regulators, including our annual report on Form 10-K and our Form 00:01:14.554 -- 00:01:17.557 10-Q filed today....